SCHEMBL23329079

SCHEMBL23329079

CCCCNC(=S)NCCCS(=O)(=O)OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 3/20 0.42
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.39
EPHX1 P07099 2/20 0.39
ACHE P22303 1/20 0.39
MMP2 P08253 1/20 0.39
EPHX2 P34913 1/20 0.39
PABPC1 P11940 1/20 0.38
ALOX12 P18054 2/20 0.38
CA12 O43570 1/20 0.38
CA14 Q9ULX7 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23328892 0.95 KMT2A (0.41) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL23328734 0.86 EPHX1 (0.55) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL23329077 0.79 EPHX2 (0.50) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL23328389 0.79 EPHX1 (0.55) MEN1KMT2AHTTALDH1A1LMNA
SCHEMBL17219 0.78 KMT2A (0.57) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL23328891 0.78 ALDH1A1 (0.46) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL2383762 0.76
SCHEMBL23328424 0.76 KMT2A (0.46) MEN1KMT2AHTTALDH1A1SMN1; SMN2
SCHEMBL7019733 0.76 KDM4E (0.52) ALDH1A1SMN1; SMN2
SCHEMBL14860830 0.74 KMT2A (0.53) MEN1KMT2AHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701333-B2 Antibacterial compounds Kent Innovation & Enterprise (GB) 2023-07-18 US disclosed
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11701333-B2 Antibacterial compounds ARF1, ARL1, TLR1 MEN1 1300/4885KMT2A 2533/4885HTT 2350/4885
US-20210128501-A1 ANTIBACTERIAL COMPOUNDS ARF1, ARL1, TLR1 MEN1 1300/4885KMT2A 2533/4885HTT 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.